Mass Eye

Nov 27, 2024 | medicalxpress.com | Mass Eye

A preclinical study by Mass Eye and Ear investigators showed that a novel mRNA-based therapy may be able to prevent blindness and scarring from proliferative vitreoretinopathy (PVR) following a retinal detachment repair or traumatic injury to the eye. There is no current treatment for PVR other than surgery, which itself carries a high risk of causing or exacerbating PVR.

Nov 21, 2024 | scienceblog.com | Mass Eye

A clinical trial has shown that sodium oxybate, a medication that mimics some effects of alcohol, can significantly improve speaking ability in people with laryngeal dystonia who experience symptom relief from alcohol.

Nov 20, 2024 | medicalxpress.com | Mass Eye

Laryngeal dystonia (LD), a rare neurological disease that significantly impacts a person's ability to speak due to uncontrollable vocal cord spasms, can have a debilitating effect on a person's social life, employment and mental health. Currently, LD is most commonly managed with botulinum neurotoxin (Botox) injections, but this treatment is ineffective for up to 40% of patients who receive it.

Jul 11, 2024 | medicalxpress.com | Mass Eye

Mass Eye and Ear researchers restored hearing in preclinical mouse models with a specific form of inherited deafness called DFNA50 caused by mutations in microRNA, by using a novel in vivo CRISPR genome editing approach. Since mouse and human microRNAs have identical sequences, the researchers hope this work can one day be translated into applications for humans.

Jul 3, 2024 | scienceblog.com | Mass Eye

A study from Mass Eye and Ear has uncovered a concerning connection between widely prescribed weight loss medications and an uncommon but serious eye condition. The research, published today in JAMA Ophthalmology, suggests that patients taking semaglutide-based drugs like Ozempic and Wegovy face a higher risk of developing a form of blindness caused by optic nerve disease.